IKNA

Ikena Oncology, Inc.

1.68 USD

Last updated Dec 6, 18:22 UTC

Yesterday HIGH

$1.56

Yesterday LOW

$1.46

52w HIGH

$7.64

52w LOW

$1.02

EPS

-0.4

PE

-4.20

Next Earnings

Mar 12, 2024

Overview News Government Trades

Ikena Oncology, Inc. stock is down -57.58% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November. 100% of analysts rate it a buy.

Ikena Oncology, Inc. focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

ikenaoncology.com

richadhand@benzinga.com

Mon Aug 7, 2023

HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $18 Price Target

HC Wainwright & Co. analyst Andres Maldonado reiterates Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $18 price target.
Benzinga Newsdesk

Mon Aug 7, 2023

Ikena Oncology Closes Acquisition Of Pionyr Immunotherapeutics In All-Stock Transaction;

Ikena acquired all of Pionyr's assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible preferred stock
richadhand@benzinga.com

Wed May 24, 2023

HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $18 Price Target

HC Wainwright & Co. analyst Andres Maldonado reiterates Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $18 price target.
Benzinga Insights

Tue May 16, 2023

Analyst Ratings for Ikena Oncology
richadhand@benzinga.com

Tue May 16, 2023

Credit Suisse Reiterates Outperform on Ikena Oncology, Maintains $13 Price Target

Credit Suisse analyst Judah Frommer reiterates Ikena Oncology (NASDAQ:IKNA) with a Outperform and maintains $13 price target.
Happy Mohamed

Mon May 15, 2023

CORRECTION: Ikena Oncology Q1 EPS $(0.39) Beats $(0.47) Estimate, Sales $5.31M Beat $4.61M Estimate

Ikena Oncology (NASDAQ:IKNA) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.47) by 17.02 percent. This is a 17.02 percent increase over losses of $(0.47) per share from
Benzinga Newsdesk

Mon May 15, 2023

Ikena Oncology Q1 EPS $(0.39) Beats $(0.47) Estimate, Sales $5.31M Beat $4.61M Estimate

Ikena Oncology (NASDAQ: IKNA) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.47) by 17.02 percent. This is a 17.02 percent increase over losses of $(0.47) per share from the same period last year.
Benzinga Newsdesk

Mon May 15, 2023

Ikena Oncology Raises $40M Via Secondary Stock Offering Of 6.11M Shares At $6.55 Per Share

Ikena Oncology, Inc. (NASDAQ:IKNA, ", Ikena", , ", Company", )))), a targeted oncology company forging new territory in patient-directed cancer treatment, announced today the pricing of an
Benzinga Newsdesk

Thu May 4, 2023

HC Wainwright & Co. Assumes Ikena Oncology at Buy, Announces Price Target of $18

HC Wainwright & Co. analyst Andres Maldonado assumes Ikena Oncology (NASDAQ:IKNA) with a Buy rating and announces Price Target of $18.
richadhand@benzinga.com

Fri Mar 17, 2023

HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $22 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $22 price target.